# Tern Plc significant progress across portfolio companies during 2022

- Link: https://www.directorstalkinterviews.com/tern-plc-significant-progress-across-portfolio-companies-during-2022/4121099339
- Published: 2023-01-25T07:09:57+00:00
- Author: Giles

**[Tern Plc](https://www.directorstalkinterviews.com/company/tern-plc/tern.l)** (
[LON:TERN](https://www.directorstalkinterviews.com/company/tern-plc/tern.l)), the
company focused on value creation from Internet of Things technology businesses,
has provided an update on the recent activities of its portfolio companies.

**Highlights**

·    Further significant progress across Tern’s portfolio companies during 2022,
with important year-on-year growth in the number of recurring revenue contracts.

·    Device Authority continued its positive business momentum in 2022, with the
business being particularly focused on growing recurring revenues from its software
security platform, KeyScaler®.  Device Authority recorded a material increase in
multi-year bookings and annual recurring revenues (“ARR”) compared to those achieved
in 2021.  This included new customer wins in the UK, the EU and US, as well as closing
their first KeyScaler® software as a service (“KSaaS”) and ‘Edge’ contracts, following
the release of new product capability.

·    In December 2022, Wyld Networks launched its pioneering satellite IoT network
service providing 100% global connectivity for the IoT. Wyld Networks has signed
over 40 alliances with launch partners from a wide array of sectors and built a 
significant purchase order book for Wyld Connect units along with data service orders.
In aggregate, Wyld has announced orders of approximately SEK 53 million (approximately
£4.2 million), that are anticipated to contribute revenue to the business in 2023.

·    FundamentalVR made excellent progress in 2022 and was the first of Tern’s investee
companies to achieve a Series B growth equity financing round in August 2022, providing
an initial £13.2 million, supported by new institutional investors.  This funding
is supporting further global deployments of FundamentalVR’s Fundamental Surgery 
platform for surgical training.

·    Following Konektio’s fundraise in December 2021, the focus for Konektio in 
2022 was on the completion of the productisation of the next release of its AssetMinder
® platform, using a product-led growth model to incorporate new customer driven 
features.  During 2022, Konektio also released new AssetMinder® modules, expanded
its sales organisation and further honed the organisation to add scale to the business.
Additionally, Matthew Scherba, a director of Tern, joined the Konektio executive
team at the start of 2023 to assist with the development of the Konektio business,
a secondment that has now been extended for an indefinite period.

·    During 2022 Talking Medicines redefined its go-to-market strategy with a focus
on selling to the larger advertising agencies who work on behalf of major pharmaceutical
companies, where Talking Medicines seeks to be retained by those agencies to supply
patient intelligence.  This strategy has successfully led to a number of global 
advertising agencies and networks engaging Talking Medicines for proof of concept
and paid subscriptions, which is expected to lead to significant revenue growth 
in 2023.

**Commenting Al Sisto, CEO of Tern, said**:

_“The goal of Tern is to help build companies, providing them with the capital and
hands-on support they need, including introducing third party investors, so that
they have the means to flourish and grow to the point where Tern can exit and deliver
quantifiable returns to its shareholders.  Each of our companies is at a different
stage in this journey and despite the continuing challenging macroeconomic environment,
our optimism around the potential from Tern’s investment strategy and our portfolio
companies continue to grow.  We believe that each of our companies has, and continues
to make, substantial progress towards the point where it will be appropriate for
Tern to exit when the market conditions are right._

_“However, as I have previously said, building great companies takes time and resources.
As each company experiences increasing customer and market interest, it brings consequent
challenges and opportunities.  In particular, the interest they are experiencing
from a broader set of investors, the majority of whom have significantly greater
financial firepower than Tern, sees such investors seeking to capture value from
our companies, at the expense of Tern.  This recognition of value creation requires
Tern to have the financial firepower to offer our companies more than just our hands-
on approach in order to protect and enhance the Tern position for our shareholders.
We have therefore continued to strengthen our balance sheet with two fundraises 
in the latter part of 2022 and will continue to deploy these funds to protect our
interests, strengthen our companies and assist their growth as we believe is appropriate
to generate shareholder value._

_“Our hands-on approach has been further demonstrated by the secondment of Matthew
Scherba, a director of Tern, to the Konektio executive team.  Matthew’s secondment
has now been extended for an indefinite period so that Tern can directly assist 
with the development of the Konektio business.  We believe this will result in Konektio
ultimately delivering a higher return for Tern shareholders and in the meantime 
reduces Tern’s costs._

_“The goal of our model, at the point any of our portfolio companies reach sufficient
maturity and the market dynamics are appropriate, continues to be to provide our
shareholders with continuous access to returns as we exit investments.  We are continually
evaluating the future for our companies and will explore and exploit any appropriate
exit opportunities as they are presented or can be originated.”_

Note: ‘Tern’s portfolio companies’ or ‘its companies’ or ‘our portfolio companies’
or ‘our companies’: Device Authority Limited, Wyld Networks AB, InVMA Limited (trading
as Konektio), FVRVS Limited (trading as FundamentalVR) and Talking Medicines Limited,
which are companies Tern has interests in and excludes Push Technology Limited, 
in which Tern has a <1% holding and minimal influence.

**Portfolio Company Update**

**Device Authority Limited** (“Device Authority”)

_Holding: 53.8%_

Device Authority is a global leader in securing machine identities and enabling ‘
zero trust’ security policies for IoT. Device Authority’s KeyScaler® software security
platform is believed to be the only platform to automate and manage machine identities
throughout their lifecycle, delivering automated device provisioning, authentication,
credential management, policy-based end-to-end data security/encryption and secure
updates and providing complete device, data and operational trust.

Device Authority continued its positive business momentum in 2022, with the business
being particularly focused on growing recurring revenues from KeyScaler®.  Device
Authority recorded a material increase in multi-year bookings and ARR compared to
those achieved in 2021.  This included new customer wins in the UK, the EU and US,
as well as closing their first KeyScaler® software as a service (“KSaaS”) and ‘Edge’
contracts, following the release of new product capability.

New commercial agreements were signed in Device Authority’s key sectors of automotive,
industrial, healthcare and US Government, including a US$1.2 million agreement over
five years, with a tier one automotive supply chain customer in December 2022, and
further agreements to secure IoT machinery, healthcare devices, smart devices for
utilities and electric vehicle companies in both the automotive and heavy machinery
sectors.

The Virginia Innovative Partnership Corporation (“VIPC”) project, in conjunction
with Crossroads Innovation Group, which is focused on US IoT security standards 
securing IoT infrastructure, as announced on 16 March 2022, has been successfully
built and deployed. Phase two of this project has commenced to extend demonstrator
proof of concept to secure digital environments and critical infrastructure for 
US agencies, as well as in private sector organisations.  This combined solution
approach, which includes multiple participants, aims to provide critical cybersecurity
proof points across a range of technologies involved in the deployment of diverse
IoT technologies and use-cases.

Device Authority’s commercial partnerships with Entrust, Venafi and Microsoft have
also continued to develop over the past year. The first KSaaS contracts were sold
via the Microsoft Marketplace, and Device Authority was accepted into the Microsoft
IP co-sell ready programme, providing both Microsoft and Microsoft partners with
commercial incentives for selling KeyScaler®. Device Authority’s global collaboration
with Entrust has been focused on sales enablement and executing a joint go-to-market
strategy targeting key customer accounts with an integrated joint offering for digital
identity.  This partnership is expected to continue to develop in 2023 across the
US, EU and APAC regions.

More recently, on 18 January 2022, Device Authority announced that it had partnered
with CYFIRMA, a leading external threat landscape management platform company, based
in Singapore to integrate CYFIRMA’s rich, real-time threat data with Device Authority’s
KeyScaler® platform to provide the intelligence to automatically detect and remediate
threats to edge networks, devices and applications.  The combined offering is designed
to give enterprises end-to-end visibility of organisation-wide threats, risks and
vulnerabilities, all from an outside-in perspective.

The release of the KeyScaler® 7 platform has introduced a robust new capability 
for Edge environments, providing fully automated identity lifecycle management, 
and a new ‘Authorization Service Connector’ enabling continuous validation of devices,
a proactive best-practice security approach for achieving ‘Zero Trust’.  This automates
the provisioning and management of certificates for both online and offline Edge
devices, including complex Nested Edge set-ups for industrial use cases, further
aligning KeyScaler® with Microsoft’s strategy of enabling companies to build more
resilient supply chains by extending cloud capabilities to remote and offline settings.

Additionally, KeyScaler’s enhanced ‘Authorization Service Connector’, introduced
in 2022, provides a framework for continuous assurance and authorisation to support
the new Software Bill of Materials requirement outlined in the White House Executive
Order 14028, and to help organisations comply with the EU Cyber Resilience Act. 
It enforces real-time authentication check-ins with external threat detection platforms
to assess threat levels for devices, mitigates new threats, and helps remediate 
against critical vulnerabilities found in device software.

Device Authority has become a market leader in its field of IoT identity and access
management, validated through independent market analysts in the 2022 SPARK Matrix
™️ for ‘IoT Identity & Access Management’.  Additionally, ABI Research, in its annual‘
Top Technology Companies’ whitepaper, confirmed Device Authority as overall leader
in ‘IoT Device Identity Lifecycle Management’, and a ‘Top Innovator and Implementer’.

**Wyld Networks AB** **(publ)** (“Wyld Networks” or “Wyld”)

_Holding: 41.2%_

Wyld Networks, quoted on the NASDAQ First North Growth Market in Stockholm, enables
affordable connectivity across the globe in areas where wireless coverage is unavailable.
The company specialises in providing wireless connectivity between IoT sensors and
Low-Earth-Orbit (“LEO”) satellites with its Wyld Connect solution.

In December 2022, Wyld launched its pioneering satellite IoT network service, providing
100% global connectivity for the IoT. According to Wyld Networks’ research only 
approximately 15% of the world’s surface currently has access to the internet.  
According to McKinsey, it is this lack of global connectivity that is holding back
the growth of the IoT from adding US$ 2-3 trillion to the global GDP over the next
ten years^(1).  Wyld Connect solves this problem by allowing businesses and governments
to connect their IoT devices anywhere in the world using LEO satellites to collect
data to improve their operational efficiencies and support their [sustainability](https://www.directorstalkinterviews.com/sustainability-green-stocks-news)
goals.  With the launch of the satellite IoT network service, Wyld can address in
part the satellite IoT market demand, which according to a forecast by Rethink IoT,
will be worth US$5.9bn by 2025.^(2)

Wyld have signed over 40 alliances with launch partners from a wide array of sectors,
including signing during 2022 with Agrology (USA), Snow Acres (Canada), TrakAssure(
USA), Axceta (Canada), Instituto Constanta De Inovação (Brazil), Hazera (Israel),
Treevia (Brazil), Constanta Industrial (Brazil), Brinja (Sweden), HartBR (Brazil),
IMAE (Brazil) and DEWA (UAE). ATSS (Saudi Arabia), Khomp (Brazil), IoTMaxi (Brazil),
British American Tobacco (Brazil), and Spider Digital (UAE, UK, North America and
Bangladesh).

Additionally, Wyld Networks has partnered with Miromico, a Swiss IoT company, to
resell Wyld Connect and focus on integrated circuits, electronic systems and software
products to meet the growing demand for connectivity for the IoT.

On 8 December 2022, Wyld Networks announced that it had a purchase order book of
approximately SEK 34 million (approximately £2.7 million) for both Wyld Connect 
units along with data service orders.  Since that date, Wyld Networks has announced
two further significant orders of SEK 12.6 million (approximately £1 million) and
SEK 6.29 million, (approximately £0.5 million) respectively.  Wyld Networks anticipates
starting to convert its order book into revenue for the business in 2023, together
with entering into additional partnerships and customer agreements, as it continues
to solve the complex problem of connecting data at low power to LEO satellites and
delivering that data to the customers that need it.

Sources:

^(1)^( )[Agriculture’s technology future: How connectivity can yield new growth](https://www.mckinsey.com/industries/agriculture/our-insights/agricultures-connected-future-how-technology-can-yield-new-growth)–
McKinsey Center for Advanced Connectivity and the McKinsey Global Institute

^(2)^( )[Nanosats and new use cases will propel satellite IoT to $5.9bn by 2025](https://rethinkresearch.biz/articles/nanosats-and-new-use-cases-will-propel-satellite-iot-to-5-9bn-by-2025/)
[](https://rethinkresearch.biz/articles/nanosats-and-new-use-cases-will-propel-satellite-iot-to-5-9bn-by-2025/)
[– Rethink IoT (rethinkresearch.biz)](https://rethinkresearch.biz/articles/nanosats-and-new-use-cases-will-propel-satellite-iot-to-5-9bn-by-2025/)

**FVRVS Limited** (“FundamentalVR”)

_Holding:_ _16.58%_

FundamentalVR delivers virtual reality (“VR”) haptic ‘flight simulators’ for surgery
creating a safe, measurable and repeatable space to refine skills.  FundamentalVR’s
goal is to transform the way surgeons prepare, practice and refine their skills.
It has built an immersive, surgical simulation application platform, Fundamental
Surgery, to provide medical professionals with the opportunity to rehearse, practice,
and test themselves within a safe, controllable space that is as close to real-life
as possible.

FundamentalVR made excellent progress in 2022 and was the first of Tern’s investee
companies to achieve a Series B growth equity financing round in August 2022, providing
an initial £13.2 million, supported by new institutional investors.  This funding
is supporting further global deployments of FundamentalVR’s Fundamental Surgical
platform for surgical training.

Key successful deployments of FundamentalVR’s technology in 2022 included with CMR
Surgical, a global surgical robotics business, where its Versius Virtual Reality
solution, produced in partnership with FundamentalVR, became the first soft-tissue
surgical robotics system to offer virtual reality (“VR”) training and was launched
as part of CMR Surgical’s ‘Surgical Professional’ education program.

FundamentalVR has continued to build out its platform capabilities and Tern believes
it is unique in being able to offer customers a scalable range of VR solutions from
standalone VR through to FundamentalVR’s flagship patented HapticVR which enables
full skills transfer.

The company’s CollaborationVR system is increasingly being utilised by customers
across the globe, allowing surgical experts to come together in virtual learning
spaces without the need for physical travel. For example, FundamentalVR and Houston
Methodist Institute for Technology, Innovation and Education (MITIE℠) recently announced
the introduction of the MITIEverse™, an extensive collaboration and shared space
learning environment.

FundamentalVR has been recognised globally as a leader in its field, being awarded
the ‘Best Mixed Reality Solution’ at the AX Awards 2022 and nominated for ‘Most 
Innovative Product’, ‘Best Education and Training Solution’ and ‘Best Mixed Reality
Solution’. at the XR Awards, together with being nominated for ‘Best Healthcare 
and Wellness Solution’ at the AWE 2022 Auggie Awards.

**_InVMA Limited_** _(trading as “Konektio”)_

_Holding: 36.8%_

Following Konektio’s £2.125 million fundraise in December 2021, led by fund managers
Foresight and Mercia, the focus for Konektio in 2022 was on further developing its
AssetMinder® modular, industry 4.0, IoT (software as a service) SaaS platform and
building an appropriate organisation to further scale the business.

During 2022 Konektio released new AssetMinder® modules, including ‘Predict’, to 
enable predictive analytics so that customers can minimise unplanned downtime, and‘
Impact’, which enables optimisation of customer maintenance schedules, allowing 
them to monitor high energy consumption processes and the environmental impact of
their machines.  Konektio is experiencing strong demand for both modules.

To support this growth, Konektio has expanded its sales organisation, hiring key
senior salespeople in Europe and the US.  Additionally, Matthew Scherba, a director
of Tern, joined the Konektio executive team at the start of 2023, for an initial
two-month secondment period, which has now been extended to be an ongoing secondment,
terminable by either Tern or Konektio on four weeks’ notice, to assist with the 
development of the Konektio business and the completion of the productisation of
the next release of AssetMinder®.

**Talking Medicines Limited** (“Talking Medicines”)

_Holding: 23.8%_

Talking Medicines is a data technology company using artificial intelligence, natural
language processing and machine learning as social listening technologies to give
patients a voice.  

In 2022 Talking Medicines redefined its go-to-market strategy with a focus on selling
to the larger advertising agencies who work on behalf of major pharmaceutical companies,
where Talking Medicines is seeking to be retained by those agencies to supply patient
intelligence.  This strategy has successfully led to a number of global advertising
agencies and networks engaging Talking Medicines for proof of concept and paid subscriptions,
which is expected to lead to significant revenue growth in 2023.

Led by Talking Medicines’ Chief Customer Officer, based in New York, who was appointed
in Q1 2022, the Talking Medicines team has been focussed on the expansion of revenue
within the advertising agency network groups through offering trials as a mechanism
to win sales.  Clients trial the PatientMetRx® platform alongside their current 
solution to experience the difference.  Sign-ups to the trials have significantly
exceeded Talking Medicines’ management’s expectations in recent months.

Through the trial undertaken, Talking Medicines has been able to demonstrate greater
efficiency and effectiveness to its clients through its unique artificial intelligence
classification models that curate the patient voice, with clients reporting on average
an 80% time saving on data collection.

In 2022 PatientMetRx® was transformed from the display of a Patient Confidence Score
™, providing a measure of brand health for medicines, to a platform with depth that
allows advertising agency clients to create impactful patient-led messaging to win
and retain business with their pharmaceutical clients.  Feature developments in 
2022 have enabled clients to discover and measure patient insights across drugs 
and therapy areas of interest in a way that was not previously possible.

In 2023, Talking Medicines will be focused on establishing a repeatable commercial
model based on the work it has done to date, including seeking subscribers for the
artificial intelligence models that already classify the patient voice across a 
significant number of top drug brands.  Additionally, PatientMetRx 2.0 is in development,
based on feedback from clients, which will seek to integrate prediction into the
offering, based on the next stage of the company’s artificial intelligence modelling.

In December 2022, a leading US-based pharmaceutical marketing publication, PM360,
announced that Talking Medicines was the winner of its ‘Most Innovative Services
to Advertising Agencies’ award.

**Online Investor Presentation and Q&A Session**

Tern’s management and management from certain of Tern’s portfolio companies will
be hosting an online presentation and Q&A session at 5 p.m. GMT on Tuesday 7 February
2023. This session is open to all existing and prospective shareholders.

Those who wish to attend should register via the following link where they will 
be provided with access details:

https://us02web.zoom.us/webinar/register/WN_BBh-OCkhT8C413sPS3Wsrw

Participants will have the opportunity to submit questions during the session, but
questions are welcomed in advance and may be submitted to: [tern@investor-focus.co.uk](https://www.directorstalkinterviews.com/tern-plc-significant-progress-across-portfolio-companies-during-2022/tern@investor-focus.co.uk).

Share on:
